This inventor holds 4 USPTO granted patents. Top assignees: Aventis Pharma Deutschland, Gmbh, Albert-Ludwigs-Universitat Freiburg, Elegene Gmbh. Active years: 2002-2018.
Location History:
- Gröbenzell, DE (2002 - 2004)
- Freiburg, DE (2004 - 2018)
Company Filing History:
2 out of 330 
1 out of 94 
1 out of 1 Years Active: 2002-2018
Title: Ralf Baumeister: Innovator in Cancer Therapy
Introduction
Ralf Baumeister is a notable inventor based in Freiburg, Germany. He has made significant contributions to the field of cancer therapy through his innovative research and development of new medical treatments. With a total of 4 patents to his name, Baumeister's work focuses on the modulation of biological interactions that are crucial in the treatment of diseases.
Latest Patents
Among his latest patents, Baumeister has developed modulators of the interaction of astrin and raptor, which have potential applications in cancer therapy. This invention relates to the treatment of mTOR-related diseases, such as cancer, by utilizing these modulators. Additionally, he has patented a method for investigating the suitability of a material as a medicament. This method involves using a nematode that has been exposed to a test substance and subsequently subjected to a local thermal stimulus.
Career Highlights
Throughout his career, Ralf Baumeister has worked with prominent companies in the pharmaceutical industry, including Aventis Pharma Deutschland GmbH and Elegene GmbH. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in the medical field.
Collaborations
Baumeister has collaborated with several professionals in his field, including Nicole Wittenburg and Edmund Hoppe. These partnerships have facilitated the exchange of ideas and fostered innovation in his research endeavors.
Conclusion
Ralf Baumeister's contributions to cancer therapy through his patents and collaborations highlight his role as a significant innovator in the medical field. His work continues to pave the way for advancements in treatment options for mTOR-related diseases.